Literature DB >> 17497104

[Humoral and cellular immune response in HPV vaccination].

E Glastetter1, A M Kaufmann.   

Abstract

Human papillomaviruses (HPV) infect skin or mucosal epithelia causing warts and dysplasia. Infections with certain high-risk HPV types in the anogenital tract can lead to malignant transformation. Cervical cancer is the second most common malignant disease in young women responsible for 275000 deaths annually worldwide. More than 50% of sexually active people acquire HPV infections over their lifetime. Around 80% of infections remain subclinical and are cleared by the immune system. Recently prophylactic vaccines against the two most common high-risk types HPV16 and 18, and additionally low-risk types HPV6 and 11, respectively, have become available. We present an overview concerning recent knowledge on natural and vaccine-induced immunity against HPV infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497104     DOI: 10.1007/s00105-007-1339-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  35 in total

1.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.

Authors:  K Münger; W C Phelps; V Bubb; P M Howley; R Schlegel
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

2.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

3.  HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination.

Authors:  A M Kaufmann; J Nieland; M Schinz; M Nonn; J Gabelsberger; H Meissner; R T Müller; I Jochmus; L Gissmann; A Schneider; M Dürst
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

4.  Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Authors:  Peter Ohlschläger; Wolfram Osen; Kerstin Dell; Stefan Faath; Robert L Garcea; Ingrid Jochmus; Martin Müller; Michael Pawlita; Klaus Schäfer; Peter Sehr; Caroline Staib; Gerd Sutter; Lutz Gissmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.

Authors:  Victor Valdespino; Clara Gorodezky; Vianney Ortiz; Andreas M Kaufmann; Edgar Roman-Basaure; Alejandra Vazquez; Jaime Berumen
Journal:  Gynecol Oncol       Date:  2005-01       Impact factor: 5.482

6.  Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors:  Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

7.  Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

Authors:  Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-02       Impact factor: 4.254

Review 8.  Natural history and epidemiological features of genital HPV infection.

Authors:  A Schneider; L A Koutsky
Journal:  IARC Sci Publ       Date:  1992

9.  Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution.

Authors:  F P Booy; R B Roden; H L Greenstone; J T Schiller; B L Trus
Journal:  J Mol Biol       Date:  1998-08-07       Impact factor: 5.469

10.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

View more
  1 in total

Review 1.  [Differential diagnosis of condylomata acuminata. Indication for histopathology].

Authors:  G Gross
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.